DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer

Information source: AstraZeneca
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Breast Cancer

Intervention: Anastrozole (Drug)

Phase: N/A

Status: Completed

Sponsored by: AstraZeneca

Official(s) and/or principal investigator(s):
H Brasch, Study Director, Affiliation: AstraZeneca Germany


The purpose of this study is the initial/followed by 5 year adjuvant therapy with Anastrozole.

Clinical Details

Official title: Postmenopausal Women With Early Hormone-Receptor Positive Breast Cancer/no Metastasis

Study design: Observational Model: Case-Only, Time Perspective: Prospective

Primary outcome: evaluation of Anastrozole therapy as adjuvant treatment in post.menopausal women with not advanced breast cancer únder naturalistic conditions

Secondary outcome:

description of population treated with anastrozole

further information about the change of specific laboratory parameters


Minimum age: N/A. Maximum age: N/A. Gender(s): Female.


Inclusion Criteria:

- Postmenopausal women with early hormone receptor positive breast cancer/no metastasis

Exclusion Criteria:

- None

Locations and Contacts

Additional Information

Starting date: May 2005
Last updated: March 19, 2008

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017